CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 3470-A |

# Specialty Guideline Management

# Enhertu

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Enhertu | fam-trastuzumab deruxtecan-nxki |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

#### HER2-positive Breast Cancer

Enhertu is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received a prior anti-HER2 based regimen either:

* in the metastatic setting, or
* in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.

#### HER2-low and HER2-ultralow Breast Cancer

* Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-low [immunohistochemistry score (IHC) 1+ or IHC 2+/ in situ hybridization test (ISH) negative] breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
* Enhertu is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

#### Gastric or Gastroesophageal Junction Adenocarcinoma

Enhertu is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

#### Non-Small Cell Lung Cancer (NSCLC)

Enhertu is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

#### Solid Tumors

#### Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

### Compendial Uses2-5

* HER2-positive breast cancer, treatment of recurrent disease
* HER2-low and ultralow breast cancer, treatment of recurrent disease
* Non-small cell lung cancer with HER2 mutations, treatment of recurrent and advanced disease
* HER2-amplified colorectal cancer (including appendiceal and anal adenocarcinoma)
* HER2-positive esophageal, gastric or gastroesophageal junction cancer
* HER2-positive cervical cancer
* HER2-positive endometrial carcinoma
* HER2-positive salivary gland tumor
* HER2-positive ovarian cancer
* HER2-positive vaginal cancer
* HER2-positive biliary tract cancer
* HER2-positive solid tumors

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review: human epidermal growth factor receptor 2 (HER2) status (e.g., immunohistochemistry (IHC) score, in situ hybridization (ISH) test) and hormone receptor (HR) status.

## Coverage Criteria

### Breast cancer1,2

Authorization of 12 months may be granted for treatment of breast cancer when any of the following criteria are met:

* Member has HER2-positive breast cancer and meets all of the following criteria:
  + The disease had no response to preoperative systemic therapy, or the disease is recurrent, metastatic, or unresectable
  + The requested medication will be used as a single agent.
* Member has HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer and meets all of the following criteria:
  + The disease had no response to preoperative systemic therapy, or the disease is recurrent, metastatic or unresectable
  + The requested medication will be used as a single agent
* Member has HER2-ultralow (IHC 0 with membrane staining) breast cancer and meets all of the following criteria:
  + The disease is recurrent metastatic or unresectable
  + The disease is hormone receptor positive with visceral crisis or endocrine therapy refractory or the disease is hormone receptor negative
  + The requested medication will be used as a single agent

### Non-small cell lung cancer1,2

Authorization of 12 months may be granted for subsequent treatment of non-small cell lung cancer with HER2 (ERBB2) mutations when all of the following criteria are met:

* The disease is recurrent, advanced, metastatic or unresectable
* The requested medication will be used as a single agent
* The member has not experienced disease progression on a HER2 targeted drug (e.g., Enhertu, Kadycla)

### Colorectal Cancer2-4

Authorization of 12 months may be granted for treatment of colorectal cancer (including appendiceal and anal adenocarcinoma) with HER2-amplified disease as a single agent when the requested medication will be used as subsequent therapy for progression of advanced or metastatic disease.

### Esophageal, Gastric or Gastroesophageal Junction Adenocarcinoma1,2

Authorization of 12 months may be granted for members with HER2-positive disease who are not surgical candidates or for subsequent treatment of HER2-positive locally advanced, recurrent or metastatic esophageal, gastric or gastroesophageal junction adenocarcinoma as a single agent.

### Cervical Cancer2

Authorization of 12 months may be granted for subsequent treatment of recurrent or metastatic HER2-positive (IHC 3+ or 2+) cervical cancer when used as a single agent.

### Endometrial Carcinoma2

Authorization of 12 months may be granted for subsequent treatment of recurrent HER2-positive (IHC 3+ or 2+) endometrial carcinoma when used as a single agent.

### Salivary Gland Tumor2,5

Authorization of 12 months may be granted for treatment of recurrent, unresectable or metastatic HER2-positive salivary gland tumor when used as a single agent.

### Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer2

Authorization of 12 months may be granted for treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer when all of the following criteria are met:

* The member has platinum-resistant persistent or recurrent disease
* The disease is HER2-positive (IHC 3+ or 2+)
* The requested medication will be used as a single agent

### Solid Tumors1,2

Authorization of 12 months may be granted for treatment of solid tumors when all of the following criteria are met:

* The disease is unresectable, metastatic, advanced, recurrent or persistent
* The tumor is HER2-positive (IHC 3+ or 2+)
* The member received prior systemic treatment and has no satisfactory alternative treatment options
* The requested medication will be used as a single agent

### Vaginal Cancer2

Authorization of 12 months may be granted for subsequent treatment of recurrent or metastatic HER2-positive (IHC 3+ or 2+) vaginal cancer when used as a single agent.

### Biliary Tract Cancer2

Authorization of 12 months may be granted for subsequent treatment of unresectable or resected gross residual (R2) disease or metastatic HER2-positive (IHC 3+) biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer) when used as a single agent.

## Continuation Of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

## References

1. Enhertu [package insert]. Basking Ridge, NJ: Daiichi Sankyo Inc.; January 2025.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. https://www.nccn.org. Accessed February 11, 2025.
3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Anal Carcinoma. Version 1.2024. Accessed September 3, 2024. https://www.nccn.org/professionals/physician\_gls/pdf/anal.pdf
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. Version 5.2024. Accessed September 3, 2024. https://www.nccn.org/professionals/physician\_gls/pdf/colon.pdf
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers. Version 4.2024. Accessed September 3, 2024. https://www.nccn.org/professionals/physician\_gls/pdf/head-and-neck.pdf.